SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Micromet Inc (MITI)
An SI Board Since February 2006
Posts SubjectMarks Bans Symbol
196 15 0 MITI
Emcee:  dr.praveen Type:  Moderated
Introduction Market Data Compact
Micromet Key facts:

Business
Design and development of novel antibody-based drugs

Markets
Cancer, Inflammation, Autoimmunity

Drug Pipeline

MT201, a fully human antibody for treatment of tumors, in phase II
MT103, a BiTE™ molecule for treatment of B cell lymphomas and leukemias, in phase I
MT110, a BiTE™ molecule for treatment of carcinomas, preclinical
MT203, a human antibody for treatment of inflammatory diseases, preclinical
D93 (humanized antibody), Solid Tumors, Pre-clinical
Additional BiTE™s and human antibodies in drug discovery

Technologies

BiTE™
BiTE™s are a novel format of bispecific antibody derivatives. They are unique in their ability to activate the body’s killer T cells against target cells. This novel mode of action translates into outstanding potency and specificity in target cell elimination.

SCA (single-chain antibodies)
SCAs are small antibody fragments, which are cost-effective to produce and extremely versatile for protein engineering. They provide an ideal structural basis for the development of novel drug formats as exemplified by their use in BiTE™ drugs.

Partners
Serono, MedImmune, Enzon, Boehringer Ingelheim

Status: Reverse merger with CNVX in Q2,2006

Proposed Ticker: MITI

Foundation
1993 as spin-off from the Institute for Immunology, Munich University

Pipeline
micromet.de

Most Interesting Research Paper:
nature.com

Reverse Merger Details and Future Goals:
biz.yahoo.com
micromet.de

Thanks for your interest!
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
196The Delaware judge denied the motion for any delay------$11.00 is the price!Arthur Radley13/1/2012
195I think it's a little late for such action--if I remember the details, AmgenArthur Radley-2/28/2012
194finance.yahoo.com Judge asked to delay Amgen acquisition of MicrometMicromet shdr.praveen-2/28/2012
193My reply sounded weird, and was meant to be praise for contributions by you, Petscaram(o)uche-1/26/2012
192Thanks for the kind words! Funny how I first learned of the deal this morning. Arthur Radley21/26/2012
191I certainly remember Peter pointing at the half-life issue, and that PB chipped scaram(o)uche-1/26/2012
190congrats to cary and peter...Peter is a silent admirer of Miti:-) PS: Is anyonedr.praveen11/26/2012
189Congrats, Cary! You are THE man........scaram(o)uche-1/26/2012
188same here. I have been holding MITI since 1$ from cnvx days. I am happy but stildr.praveen-1/26/2012
187well played. as an amgn owner, we overpaid at $11... ;) edit: interesting theymopgcw-1/26/2012
186Has been a long and lonely ride--I love AMGN, but wish they had loved us for aboArthur Radley11/26/2012
185This (NIH) funding is a nice cushion for their cash burn as normally these projeArthur Radley-1/9/2012
184MITI signs CRADA with NCI for expanded Blinatumomab trials. No specifics on funpgo-neil-1/9/2012
183We had the near 500 point move in the Dow this week, but even with some backing Arthur Radley-12/2/2011
182finance.yahoo.com Three month chart for MITI--nice double bounce off low price Arthur Radley-10/25/2011
181Needham & Company Reiterates a 'Buy' on Micromet (MITI); Signs BiTE Arthur Radley-7/11/2011
180Needham & Company Reiterates a 'Buy' on Micromet (MITI); Signs BiTE Arthur Radley-7/11/2011
179finance.yahoo.com Maybe this Amgen deal will add some value to MITI--- up frontArthur Radley-7/11/2011
178Needham & Company Maintains a 'Buy' on Micromet (MITI); Data StronglArthur Radley-6/13/2011
177MITI is in play this morning on the basis of strong results for its mab drug.Chris08-6/10/2011
176It is amazing how quiet this message board is compared with the Yahoo board whicmokelumne river-5/31/2011
175. Data Published in Journal of Clinical Oncology Highlights Significant ActivitArthur Radley-5/17/2011
174bloodjournal.hematologylibrary.org MITI had some heavy volume today.....this arArthur Radley-4/28/2011
173Needham & Company Maintains a 'Buy' on Micromet (MITI); BlinatumomabArthur Radley-3/4/2011
172Go figure........good news and the stock goes down! At least ARQL is having a niArthur Radley-1/12/2011
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News